IMMUNOMEDICS, INC.: 10-Q filed 2015-02-04
What IMMUNOMEDICS, INC. reported in its quarterly report filed 2015-02-04 (fiscal Q2 2015): 25 published measures, 69 facts as tagged in accession 0001193125-15-033714.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-02-04
- Fiscal period
- fiscal Q2 2015
- Accession
- 0001193125-15-033714 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All IMMUNOMEDICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 26,787,417 | USD | |
| At 2014-06-30 | 47,486,482 | USD | |
| At 2013-12-31 | 32,785,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 16,610,626 | USD | |
| At 2014-06-30 | 39,349,767 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 2,848,690 | USD | |
| At 2014-06-30 | 6,961,494 | USD | |
| At 2013-12-31 | 6,809,948 | USD | |
| At 2013-06-30 | 41,326,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -11,435,235 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -23,845,655 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -8,549,754 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -14,073,443 | USD | 184 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | 439,599 | USD | 184 |
| 2013-07-01 to 2013-12-31 | 214,259 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -285,311,293 | USD | |
| At 2014-06-30 | -261,465,638 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 26,892 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 38,855 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -4,501 | USD | 92 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 2,053,440 | USD | |
| At 2014-06-30 | 1,895,475 | USD | |
| At 2013-12-31 | 1,987,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -11,461,873 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -23,906,007 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -8,610,320 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -14,166,370 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 24,527,867 | USD | |
| At 2014-06-30 | 45,384,897 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 9,179,915 | USD | |
| At 2014-06-30 | 7,126,840 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 551,429 | USD | |
| At 2014-06-30 | 674,617 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 676,777 | USD | |
| At 2014-06-30 | 778,989 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 10,364,850 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 19,756,867 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 7,243,108 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 15,079,907 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 93,211,463 | shares | |
| At 2014-06-30 | 93,078,755 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 301,454,274 | USD | |
| At 2014-06-30 | 300,080,804 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -6,447 | USD | |
| At 2014-06-30 | 261,837 | USD | |
| At 2013-12-31 | 296,733 | USD | |
| At 2013-06-30 | 161,830 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 16,057,500 | USD | |
| At 2014-06-30 | 38,859,398 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 27,594,558 | USD | |
| At 2014-06-30 | 27,312,924 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 30,000 | USD | |
| At 2014-06-30 | 30,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 1,550,002 | USD | |
| At 2014-06-30 | 1,500,244 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -11,465,650 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -23,908,412 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -8,574,974 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -14,123,862 | USD | 184 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -11,520,937 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -24,113,939 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -8,482,258 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -13,938,540 | USD | 184 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 1,856,036 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 5,675,228 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 2,042,081 | USD | 92 |
| 2013-07-01 to 2013-12-31 | 3,774,752 | USD | 184 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | 281,634 | USD | 184 |
| 2013-07-01 to 2013-12-31 | 314,376 | USD | 184 |
Inspect the source
- Entity
- IMMUNOMEDICS, INC. / CIK 0000722830
- Captured
- SEC response SHA-256
d9e652f20067bb0e424f518a6160c3705c40f702f691a59fdf4f1d40e5e05b37
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000722830.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))